Media stories about Trevena (NASDAQ:TRVN) have been trending somewhat negative on Friday, Accern reports. The research group rates the sentiment of media coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Trevena earned a media sentiment score of -0.01 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 45.5391798700296 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Here are some of the media headlines that may have impacted Accern Sentiment’s analysis:
- Oppenheimer Holdings, Inc. Analysts Give Trevena, Inc. (TRVN) a $5.00 Price Target (americanbankingnews.com)
- Spooked Investors Send Trevena Inc (TRVN) Shares Spiraling; Here’s Why – Smarter Analyst (smarteranalyst.com)
- After-Hours Movers 10/11: (ARDX) (BW) (SIGM) Higher; (JILL) (TRVN) (PTGX) Lower (more…) (streetinsider.com)
- Chesco biopharm firm cuts 21 jobs as part of restructuring (finance.yahoo.com)
- Interesting TRVN Call Options For November 17th (thestreet.com)
Several analysts recently weighed in on TRVN shares. Zacks Investment Research cut Trevena from a “buy” rating to a “hold” rating in a report on Friday, August 25th. Cowen and Company reissued a “buy” rating and set a $10.00 price target on shares of Trevena in a report on Friday, August 4th. Oppenheimer Holdings, Inc. set a $5.00 price target on Trevena and gave the stock a “buy” rating in a report on Thursday. Finally, HC Wainwright dropped their price objective on Trevena from $8.00 to $7.00 and set a “buy” rating for the company in a report on Thursday. One investment analyst has rated the stock with a sell rating, one has given a hold rating and eleven have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $10.23.
Trevena (NASDAQ:TRVN) last released its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.35) earnings per share for the quarter, meeting the Zacks’ consensus estimate of ($0.35).
ILLEGAL ACTIVITY NOTICE: This news story was originally published by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this news story on another site, it was illegally copied and republished in violation of United States and international copyright legislation. The correct version of this news story can be viewed at https://sportsperspectives.com/2017/10/13/trevena-trvn-earns-media-impact-rating-of-0-01.html.
Trevena Inc is a biopharmaceutical company, which is engaged in developing various therapies. The Company is developing OLINVO, a u-receptor G protein pathway selective modulator (u-GPS) for the management of moderate-to-severe acute pain where intravenous (IV) administration is preferred. It is focused on commercializing it in the United States for use in acute care settings, such as hospitals and ambulatory surgery centers.
Receive News & Ratings for Trevena Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena Inc. and related companies with MarketBeat.com's FREE daily email newsletter.